EUCTR2012-001831-30-GB进行中（未招募）1 期
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy - ISIS 420915-CS2
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosed Stage 1 or Stage 2 FAP patient
- •Meets NIS requirements
- •Male or female aged 18 to 82 years old at the time of informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 65
排除标准
- •Has inadequate liver, renal or heart function
- •Has retinol levels at screen < LLN
- •Has human immunodeficiency virus (HIV), hepatitis B or hepatitis C
- •Has type 1 or type 2 diabetes mellitus or other cause of sensorimotor or autonomic neuropathy
- •Recently treated with another investigational drug, biological agent or device
- •Is currently taking Vyndaqel® or diflunisal
- •Prior liver transplant or anticipated liver transplant within 1 year of screening
- •Anticipated survival less than 2 years
研究者
相似试验
进行中（未招募）
不适用
A controlled study to assess the effectiveness and safety of study drug, ISIS 420915, in patients with Familial Amyloid PolyneuropathyFamilial Amyloid PolyneuropathyMedDRA version: 18.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2012-001831-30-BGIsis Pharmaceuticals, Inc.195
进行中（未招募）
1 期
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)EUCTR2020-006082-11-HUAdagio Therapeutics Inc.1,084
进行中（未招募）
1 期
A controlled study to assess the effectiveness and safety of study drug, ISIS 420915, in patients with Familial Amyloid PolyneuropathyFamilial Amyloid PolyneuropathyMedDRA version: 14.1Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2012-001831-30-ITIsis Pharmaceuticals, Inc.195
进行中（未招募）
不适用
A study in which patients suffering from moderate-to-severe psoriasis are assigned by chance, with neither the patient nor the doctor knowing the identity of the treatment in a given patient, to either the investigational drug CF101 or a matching dummy tablet, and are observed for beneficial and side effects.Moderate-to-Severe Plaque PsoriasisMedDRA version: 17.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-024196-83-BGCan-Fite BioPharma, Ltd.291
进行中（未招募）
1 期
A controlled study to assess the effectiveness and safety of study drug, ISIS 420915, in patients with Familial Amyloid PolyneuropathyEUCTR2012-001831-30-PTIonis Pharmaceuticals, Inc.135